insights_auto
Por qué ha subido 6160 4,36%?
Profundizarchevron_right
6160:HKG
BeOne Medicines AG
225,00 HKD
arrow_upward
+4,36%(+9,40) 1 d
16 oct, 16:08:14 GMT+8 · HKD
search
Todos los símbolos
| Símbolo | Precio | Cambio | % de cambio |
|---|
insights_autoGenerando estadísticas principales de 6160...
Abrir
224,80 HKD
Alto
230,20 HKD
Bajo
221,80 HKD
Cap. burs.
355,76 mil M
Vol. medio
2,93 M
Volumen
4,41 M
Ratio PER
65,67
Máximo en 52 sem.
235,60 HKD
Mínimo en 52 sem.
153,00 HKD
BPA
3,43 HKD
Acciones en circulación
1426,36 M
N.º de empleados
12 mil
Abrir
224,80 HKD
Alto
230,20 HKD
Bajo
221,80 HKD
Cap. burs.
355,76 mil M
Vol. medio
2,93 M
Volumen
4,41 M
Ratio PER
65,67
Máximo en 52 sem.
235,60 HKD
Mínimo en 52 sem.
153,00 HKD
BPA
3,43 HKD
Acciones en circulación
1426,36 M
N.º de empleados
12 mil
Noticias
De fuentes web y partners de noticias
ad-hoc-news.de
·
hace 1 día
Morgan Stanley lifts target for BeOne Medicines stock to USD 425.00
MarketBeat
·
hace 2 días
BeOne Medicines (NASDAQ:ONC) Stock: Insider Xiaodong Wang Sells 31,027 Shares
Perfil
BeOne Medicines, formerly known as BeiGene, Ltd. is a multinational oncology company. It specializes in the development of drugs for cancer treatment.
Founded in 2010 by chief executive officer John V. Oyler and Xiaodong Wang, the company is headquartered in Cambridge, Massachusetts and has locations on six continents, in over 45 countries. BeOne has a large presence in the Chinese market.
BeOne Medicines has developed several medicines, including tislelizumab, a checkpoint inhibitor, and zanubrutinib, a Bruton's tyrosine kinase inhibitor. On 14 November 2024, the company announced its intention to rebrand as BeOne Medicines. BeOne changed its stock ticker to ONC in January 2025 and redomiciled to Basel, Switzerland in May 2025. Wikipedia
Acerca de BeOne Medicines AG
CEOJohn Vincent Oyler | John Vincent Oyler
Empleados12 mil
Fundación28 oct 2010
Sede-
Sector-
Sitio webbeonemedicines.com